Literature DB >> 27313744

Clinicopathological implications of GNAS in Ewing sarcoma.

Byeong-Joo Noh1, Ji-Youn Sung1, Youn Wha Kim1, Eduardo Santini Araujo2, Ricardo Karam Kalil3, Woon-Won Jung4, Hyun-Sook Kim5, Yong-Koo Park1.   

Abstract

The objective of the present study was to determine whether guanine nucleotide-binding protein α stimulating (GNAS) gene expression correlates with pathognomonic signs by analyzing the mutations, methylation status and G-protein α subunit (Gsα) expression of GNAS in Ewing sarcoma (ES). Formalin-fixed paraffin-embedded tissue samples from 77 patients with primary ES were obtained in South Korea, Argentina and Brazil, and were studied via methylation chip assay and direct sequencing of the GNAS gene and immunohistochemical analysis of Gsα. The mutation and methylation statuses of the GNAS gene were examined. Immunohistochemical results were measured with respect to proportion and staining intensity. The results revealed that GNAS genes in ES tumor samples were less methylated compared with normal controls. No mutations were detected at exons 8 or 9 of the GNAS locus complex on chromosome 20q13.3, indicating that the pathogenesis of ES was not associated with GNAS mutation. Gsα expression correlated well with the methylation status of the GNAS gene. Notably, high Gsα expression was detected more frequently in samples from living patients than from decedents, although this was not statistically significant (P=0.055). In conclusion, GNAS mutation is not associated with the pathogenesis of ES tumors. This finding may be used to differentiate ES tumors from metastatic bone lesions with morphological similarity to ES tumors. Analysis of the methylation status of the GNAS gene and immunohistochemical Gsα expression suggests that hypermethylated GNAS (low Gsα expression) in ES may be associated with unfavorable progression with a non-significant trend.

Entities:  

Keywords:  Ewing sarcoma; GNAS

Year:  2016        PMID: 27313744      PMCID: PMC4888216          DOI: 10.3892/ol.2016.4521

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  32 in total

Review 1.  Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets.

Authors:  Stephen L Lessnick; Marc Ladanyi
Journal:  Annu Rev Pathol       Date:  2011-09-19       Impact factor: 23.472

2.  GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation.

Authors:  Jean Charles Nault; Monique Fabre; Gabrielle Couchy; Camilla Pilati; Emmanuelle Jeannot; Jeanne Tran Van Nhieu; Marie-Christine Saint-Paul; Anne De Muret; Marie-José Redon; Catherine Buffet; Sylvie Salenave; Charles Balabaud; Sophie Prevot; Philippe Labrune; Paulette Bioulac-Sage; Jean-Yves Scoazec; Philippe Chanson; Jessica Zucman-Rossi
Journal:  J Hepatol       Date:  2011-08-09       Impact factor: 25.083

Review 3.  Genetics of pituitary adenomas.

Authors:  Monica R Gadelha; Giampaolo Trivellin; Laura Cristina Hernández Ramírez; Márta Korbonits
Journal:  Front Horm Res       Date:  2013-03-19       Impact factor: 2.606

4.  Clinical effect of point mutations in myelodysplastic syndromes.

Authors:  Rafael Bejar; Kristen Stevenson; Omar Abdel-Wahab; Naomi Galili; Björn Nilsson; Guillermo Garcia-Manero; Hagop Kantarjian; Azra Raza; Ross L Levine; Donna Neuberg; Benjamin L Ebert
Journal:  N Engl J Med       Date:  2011-06-30       Impact factor: 91.245

5.  The T393C polymorphism of the G alpha s gene (GNAS1) is a novel prognostic marker in bladder cancer.

Authors:  Ulrich H Frey; Andreas Eisenhardt; Gerd Lümmen; Herbert Rübben; Karl-Heinz Jöckel; Kurt W Schmid; Winfried Siffert
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-04       Impact factor: 4.254

6.  The Ewing's sarcoma fusion protein, EWS-FLI, binds Runx2 and blocks osteoblast differentiation.

Authors:  Xiaodong Li; Meghan E McGee-Lawrence; Matthew Decker; Jennifer J Westendorf
Journal:  J Cell Biochem       Date:  2010-11-01       Impact factor: 4.429

7.  GNAS1 T393C polymorphism and survival in patients with sporadic colorectal cancer.

Authors:  Ulrich H Frey; Hakan Alakus; Jeremias Wohlschlaeger; Klaus J Schmitz; Günther Winde; Hans G van Calker; Karl-Heinz Jöckel; Winfried Siffert; Kurt W Schmid
Journal:  Clin Cancer Res       Date:  2005-07-15       Impact factor: 12.531

Review 8.  Minireview: GNAS: normal and abnormal functions.

Authors:  Lee S Weinstein; Jie Liu; Akio Sakamoto; Tao Xie; Min Chen
Journal:  Endocrinology       Date:  2004-08-26       Impact factor: 4.736

9.  Diagnostic value of investigating GNAS mutations in fibro-osseous lesions: a retrospective study of 91 cases of fibrous dysplasia and 40 other fibro-osseous lesions.

Authors:  Flore Tabareau-Delalande; Christine Collin; Anne Gomez-Brouchet; Anne-Valérie Decouvelaere; Corinne Bouvier; Frédérique Larousserie; Béatrice Marie; Christophe Delfour; Sébastien Aubert; Philippe Rosset; Anne de Muret; Jean-Christophe Pagès; Gonzague de Pinieux
Journal:  Mod Pathol       Date:  2013-02-01       Impact factor: 7.842

10.  Genetic and epigenetic states of the GNAS complex in pseudohypoparathyroidism type Ib using methylation-specific multiplex ligation-dependent probe amplification assay.

Authors:  Akiko Yuno; Takeshi Usui; Yuko Yambe; Kiichiro Higashi; Satoshi Ugi; Junji Shinoda; Yasuo Mashio; Akira Shimatsu
Journal:  Eur J Endocrinol       Date:  2013-01-17       Impact factor: 6.664

View more
  1 in total

1.  Clinical Utility of Functional Precision Medicine in the Management of Recurrent/Relapsed Childhood Rhabdomyosarcoma.

Authors:  Arlet M Acanda De La Rocha; Maggie Fader; Ebony R Coats; Paula S Espinal; Vanessa Berrios; Cima Saghira; Ileana Sotto; Rojesh Shakya; Michelin Janvier; Ziad Khatib; Haneen Abdella; Mathew Bittle; Cristina M Andrade-Feraud; Tomás R Guilarte; Jennifer McCafferty-Fernandez; Daria Salyakina; Diana J Azzam
Journal:  JCO Precis Oncol       Date:  2021-10-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.